| WARF: P02381US |  |
| Modified Retinoid Compounds with Reduced Toxicity |
| INVENTORS | • | Margaret Clagett-Dame, Hector DeLuca, Sumithra Gowlugari |
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing retinoid esters that have been modified to be significantly less toxic than the parent retinoids and can be administered orally with minimal side effects.
OVERVIEW
Orally administered retinoic acid isomers are used to treat many disorders; however, they cause serious side effects including weight loss, inanition, eye encrustation, bone loss, mucocutaneous toxicity, hyperlipidemia and teratogenic activity in patients who are pregnant.
THE INVENTION
UW-Madison researchers have developed modified retinoid esters with reduced toxicity. The carboxyl group of a retinoid is esterified with a highly sterically hindered compound, preferably a secondary or tertiary alcohol. The resulting retinoid esters are significantly less toxic than the parent retinoids and can be administered orally with minimal side effects.
APPLICATIONS
- Potentially useful for treating all diseases where retinoid compounds have been effective, including proliferative skin disorders, neoplastic diseases and skin conditions
KEY BENEFITS
- Resulting compounds can be administered orally
- Greatly reduces the risk of serious side effects typically associated with oral retinoid use
- Offer much greater therapeutic window than parent retinoids
ADDITIONAL INFORMATION
For More Information About the Inventors
Related Technologies
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Skin & connective tissue
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
WARF: A Leader in Technology Transfer Since 1925
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
